347850 - D & D Pharmatech, Inc.

347850 Summary

Biopharma

Stock Price & Overview

₩49,200 +700 (+1.44%) Close · Sep 4, 2026 KST

KOSDAQ | ₩KRW | Close: ₩49,200 ≈ US$35 · Market cap ₩2.3tn (≈ $1.6bn)

347850 Financial Statements

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022
Total Revenue	4.3	11.4	18.7	0.6
Operating Income	-34.0	-25.0	-13.5	-68.7
Finance Income	1.2	2.4	1.2	0.8
Finance Costs	-1.0	-1.3	-1.7	-3.7
Pretax Income	-24.9	-30.4	4.5	-163.5
Income Tax Expense	-0.9	-0.9	1.1	-26.5
Net Income	-24.0	-29.5	3.4	-137.0
Total Comprehensive Income	-24.6	-24.4	4.6	-127.0

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022
Total Assets	97.5	97.5	79.2	93.6
Current Assets	51.0	39.8	19.6	33.4
Cash & Cash Equivalents	32.9	30.0	15.6	25.5
Trade Receivables	2.0	5.5	1.4	0.3
Non-current Assets	46.6	57.7	59.6	60.3
Property, Plant & Equipment	5.6	7.7	6.4	3.0
Intangible Assets	30.4	34.6	41.5	44.0
Total Liabilities	18.6	27.9	24.0	75.1
Current Liabilities	5.4	11.1	7.5	54.9
Non-current Liabilities	13.1	16.8	16.5	20.2
Total Equity	79.0	69.6	55.2	18.5
Share Capital	21.8	5.3	4.6	4.0
Retained Earnings	-332.9	-309.4	-289.7	-293.6

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022
Cash from Operating Activities	-21.1	-21.8	-9.1	-53.1
Cash from Investing Activities	-0.1	-0.5	0.3	-0.5
Purchase of Property, Plant & Equipment	-0.1	-0.4	-0.0	-0.7
Cash from Financing Activities	24.2	36.3	-0.6	2.0
Net Change in Cash	3.0	13.9	-9.5	-51.6

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2
Total Revenue	0.7	0.1	1.0	1.0	0.9	1.4	5.1	1.9	2.3
Operating Income	-9.9	-11.1	-10.4	-6.2	-8.1	-9.3	-6.9	-7.0	-5.9
Finance Income	1.0	0.6	0.2	0.3	0.4	0.3	1.3	0.4	0.5
Finance Costs	-2.9	-0.2	0.1	-0.1	-0.7	-0.3	-0.4	-0.6	-0.2
Pretax Income	-8.0	-10.3	1.6	-6.0	-10.7	-9.9	-10.1	-8.3	-6.1
Income Tax Expense	—	-0.2	—	—	—	—	-0.2	-0.2	-0.2
Net Income	-7.8	-10.1	1.9	-5.8	-10.0	-10.1	-9.8	-8.1	-5.9
Total Comprehensive Income	-7.2	-8.4	2.8	-4.8	-12.5	-10.2	-6.1	-10.0	-4.6

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2
Total Assets	319.9	92.5	97.5	93.2	98.2	88.5	97.5	101.5	109.5
Current Assets	185.2	45.9	51.0	45.2	48.9	33.1	39.8	44.3	49.6
Cash & Cash Equivalents	12.3	24.6	32.9	37.9	40.0	26.1	30.0	37.8	43.3
Trade Receivables	7.0	3.9	2.0	2.3	3.1	3.3	5.5	1.7	1.5
Non-current Assets	134.8	46.6	46.6	48.0	49.3	55.5	57.7	57.2	60.0
Property, Plant & Equipment	4.9	5.5	5.6	6.0	6.4	7.3	7.7	7.7	5.8
Intangible Assets	30.8	31.1	30.4	30.5	30.3	33.6	34.6	40.1	43.1
Total Liabilities	185.8	18.5	18.6	18.3	19.9	25.4	27.9	26.8	25.5
Current Liabilities	6.8	5.7	5.4	4.6	5.6	9.3	11.1	10.8	9.2
Non-current Liabilities	179.0	12.8	13.1	13.7	14.2	16.0	16.8	16.0	16.3
Total Equity	134.1	74.0	79.0	74.9	78.3	63.2	69.6	74.7	84.0
Share Capital	22.9	21.9	21.8	5.4	5.4	5.4	5.3	5.3	5.3
Retained Earnings	-350.8	-342.4	-332.9	-334.7	-329.1	-319.2	-309.4	-308.9	-300.9

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2
Cash from Operating Activities	-7.3	-9.7	-5.2	-2.7	-7.3	-5.9	-8.3	-5.0	—
Cash from Investing Activities	-230.7	-0.0	-0.0	0.0	-0.1	-0.0	0.2	-0.6	—
Purchase of Property, Plant & Equipment	-0.0	0.0	-0.0	-0.0	0.0	-0.0	-0.1	-0.2	—
Cash from Financing Activities	225.2	1.7	0.3	0.5	21.3	2.1	0.2	-0.1	—
Net Change in Cash	-12.7	-8.0	-4.9	-2.2	14.0	-3.9	-7.9	-5.8	—

Consolidated (CFS), from DART. 4 fiscal years and 9 quarters. Accounts matched on IFRS account_id, not Korean labels, so the same line holds across years where the Korean wording changed. Quarterly figures are three-month values: income quarters from DART's three-month column, cash-flow quarters differenced from DART's cumulative figures, and Q4 as annual minus nine-month cumulative.

347850 Growth

FY2025 ₩bn	Latest	1-yr	3-yr CAGR	5-yr CAGR	10-yr CAGR
Revenue	4.3	-62.4%	+91.6%	—	—
Operating income	-34.0	—	—	—	—
Net income	-24.0	—	—	—	—
EPS	₩-523	—	—	—	—
Operating cash flow	-21.1	—	—	—	—
Shareholders' equity	79.0	+13.5%	+62.2%	—	—

Compound annual growth from the DART annual statements on this page. n/m where either end of the period is a loss or missing. EPS uses today's share count for every year.

347850 Profitability

Ratio	FY2025	FY2024	FY2023	FY2022
Operating margin	-791.0%	-218.7%	-72.2%	-11,244.2%
Net margin	-558.0%	-257.8%	18.3%	-22,442.4%
Return on equity	-32.3%	-47.3%	9.3%	-739.9%
Return on assets	-24.6%	-33.4%	4.0%	-146.3%
Operating cash flow / revenue	-491.9%	-190.7%	-48.8%	-8,694.1%
Capex / revenue	1.5%	3.5%	0.2%	116.6%

Margins divide by revenue for the same year. Return on equity and assets divide net income by the average of that year's and the prior year's balance, as DART reports them (consolidated, including minority interests).

Similar to 347850

Symbol	Last Price
145020Hugel, Inc.	₩244,000 +1.5%
302440SK Bioscience Co., Ltd.	₩37,900 +0.4%
009420Hanall Biopharma Co., Ltd.	₩54,700 +1.5%
310210Voronoi, Inc.	₩153,000 +3.9%
214370Caregen Co., Ltd.	₩44,500 +1.5%
237690ST Pharm Co., Ltd.	₩101,200 +2.2%
226950Olix Pharmaceuticals, Inc.	₩95,900 +4.5%
140410Mezzion Pharma Co., Ltd.	₩65,000 +0.0%
068760Celltrion Pharm, Inc.	₩40,850 +0.0%
007390Naturecell Co., Ltd.	₩23,950 +0.2%

Compare all 48 in Biopharma

What a US investor should know

Trading hours09:00–15:30 KST — 20:00–02:30 US Eastern the night before.
Daily limitKorean stocks can move at most ±30% in a session before trading halts.
Getting exposureKRX shares are not directly tradable in most US brokerage accounts. The usual routes are Korea ETFs or an international account.
ReportingKorean issuers file to DART, not the SEC. Half-year and quarterly reports land about 45 days after period end.